Focus Vision adds Queensland's first Ray-Tracing LASIK

By AI, Created 11:28 AM UTC, May 20, 2026, /AGP/ – Brisbane clinic Focus Vision says it is the first ophthalmology practice in Queensland to offer Ray-Tracing LASIK, a personalised vision correction system marketed as WaveLight Plus. The launch brings a newly FDA-approved technology to local patients and highlights strong study outcomes in myopia treatment.

Why it matters: - Focus Vision says Queensland patients now have local access to Ray-Tracing LASIK, a more personalised form of laser vision correction. - The technology is designed to tailor treatment to each eye’s full optical system, which could improve precision compared with older approaches. - The launch comes soon after the system received U.S. FDA approval, adding regulatory momentum to the technology.

What happened: - Focus Vision became the first ophthalmology clinic in Queensland and one of the first in Australia to offer Ray-Tracing LASIK, marketed as WaveLight Plus. - The Brisbane practice introduced the treatment using the Alcon WaveLight EX500 excimer laser and treatment plans from the InnovEyes Sightmap diagnostic platform. - The clinic said the treatment is available through ophthalmic surgeons Dr David Gunn and Dr Brendan Cronin. - Both surgeons are Fellows of the Royal Australian and New Zealand College of Ophthalmologists and are registered with the Medical Board of Australia through AHPRA.

The details: - Ray-tracing technology builds a digital model of the full optical system of each eye, including the cornea, lens and axial length. - That model is used to design a treatment tailored to the individual eye. - Earlier laser vision correction methods rely mainly on corneal topography or wavefront measurements. - In the FDA Premarket Approval study for Ray-Tracing LASIK with InnovEyes Sightmap, 94.4% of treated eyes reached uncorrected distance visual acuity of 20/20 or better at 12 months. - In the same study, 70.2% of treated eyes reached 20/16 or better. - All pre-specified safety and efficacy endpoints exceeded the study targets, and no device-related adverse events were reported. - Peer-reviewed and industry literature has described the 20/16 result as among the strongest visual acuity outcomes reported in any FDA pivotal laser vision correction study to date. - As with any surgical procedure, outcomes vary by patient and not every person is suitable for laser vision correction.

Between the lines: - Focus Vision is positioning itself around a premium, highly individualized procedure rather than standard LASIK. - The clinic’s timing suggests it wants to be an early mover in Australia as the technology enters broader clinical use. - The study results are strong, but the release also underscores that surgical candidacy still depends on a full eye assessment.

What’s next: - Patients interested in the procedure must undergo a comprehensive eye assessment to determine suitability. - Focus Vision says more information about the practice, surgeons and procedures is available at the clinic’s website. - The release also points patients to the clinic’s social channels on LinkedIn, Instagram, Facebook, YouTube and TikTok.

The bottom line: - Focus Vision is bringing an FDA-approved, highly personalized LASIK option to Queensland first, betting that better precision and strong trial data will draw patients seeking advanced vision correction.